Allogene Therapeutics reported a net margin of -918.45% for the quarter ended Jun 2026. These financial ratios cover 32 quarters of results from Sep 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||||||||
| EBT Margin | -159,563.27% | 0.97% | -204,800.00% | -119,220.31% | -301,885.19% | -360,146.15% | -333,226.67% | -348,918.18% | -258,140.91% | -361,471.43% | -291,231.82% | -918.45% | ||||||||||||||||||||
| EBIT Margin | -158,510.20% | 2.26% | -205,164.10% | -119,712.50% | -305,596.30% | -370,750.00% | -330,306.67% | -366,090.91% | -286,345.45% | -405,280.95% | -315,927.27% | -1,011.21% | ||||||||||||||||||||
| EBITDA Margin | -158,510.20% | 2.26% | -205,164.10% | -119,712.50% | -305,596.30% | -370,750.00% | -330,306.67% | -366,090.91% | -286,345.45% | -405,280.95% | -315,927.27% | -1,011.21% | ||||||||||||||||||||
| Operating Margin | -158,510.20% | 2.26% | -205,164.10% | -119,712.50% | -305,596.30% | -370,750.00% | -330,306.67% | -366,090.91% | -286,345.45% | -405,280.95% | -315,927.27% | -1,011.21% | ||||||||||||||||||||
| Net Margin | -159,563.27% | 0.97% | -204,800.00% | -119,220.31% | -301,885.19% | -360,146.15% | -333,226.67% | -348,918.18% | -258,140.91% | -361,471.43% | -291,231.82% | -918.45% | ||||||||||||||||||||
| FCF Margin | -106,581.63% | -61.03% | -182,951.28% | -66,707.81% | -177,325.93% | -245,338.46% | -225,580.00% | -282,477.27% | -252,463.64% | -256,609.52% | -247,518.18% | -689.85% | ||||||||||||||||||||
| Efficiency | ||||||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 1,102.98M | 1,065.04M | 1,014.46M | 966.86M | 925.05M | 858.03M | 785.85M | 761.57M | 743.21M | 678.12M | 614.59M | 616.62M | 618.00M | 568.91M | 528.35M | 489.29M | 455.18M | 427.84M | 405.93M | 473.02M | ||||||||||||
| Invested CapitalInvested Cap. | ||||||||||||||||||||||||||||||||
| Asset Utilization RatioAsset Util. | 0.03 | 0.11 | 0.07 | 0.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |||||||||||||||||
| Leverage & Solvency | ||||||||||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | -85.45 | 1.47 | -228.61 | -33.76 | 29.00 | -717.74 | -746.79 | -434.61 | -212.01 | -130.53 | -135.48 | -153.64 | -136.79 | |||||||||||||||||||
| Debt Ratio | ||||||||||||||||||||||||||||||||
| Times Interest Earned | -85.45 | 1.47 | -228.61 | -33.76 | 29.00 | -717.74 | -746.79 | -434.61 | -212.01 | -130.53 | -135.48 | -153.64 | -136.79 | |||||||||||||||||||
| Valuation | ||||||||||||||||||||||||||||||||
| Price to EarningsP/E | -46.82 | 0.00M | -16.38 | -21.47 | -19.08 | -9.70 | -7.20 | -10.82 | -9.39 | -7.13 | -11.89 | -7.33 | -9.00 | -7.86 | -5.33 | -4.89 | -6.70 | -8.05 | -13.95 | -16.86 | ||||||||||||
| Price to SalesP/S | 0.07M | 28.13 | 0.03M | 0.03M | 0.06M | 0.03M | 0.02M | 0.04M | 0.02M | 0.03M | 0.03M | 154.81 | ||||||||||||||||||||
| Price to BookP/B | 3.77 | 10.64 | 1.51 | 2.03 | 2.09 | 1.36 | 1.22 | 1.34 | 0.92 | 1.06 | 1.65 | 0.95 | 1.26 | 1.07 | 0.83 | 0.72 | 0.88 | 0.79 | 2.14 | 0.90 | ||||||||||||
| Enterprise Value | 3,177.22M | 1,670.63M | 858.87M | 1,147.95M | 1,003.31M | 391.20M | 248.73M | 338.69M | 67.61M | 92.64M | 377.06M | 42.46M | 295.04M | 159.53M | 39.11M | -24.37M | 24.53M | 64.09M | 330.47M | 385.71M | ||||||||||||
| EV to EBIT | -40.91 | 978.70 | -10.73 | -14.98 | -12.16 | -4.06 | -2.51 | -4.21 | -1.07 | -1.09 | -5.43 | -0.59 | -4.11 | -2.64 | -0.60 | 0.43 | -0.55 | -1.51 | -7.17 | -8.22 | ||||||||||||
| EV to EBITDA | -40.91 | 978.70 | -10.73 | -14.98 | -12.16 | -4.06 | -2.51 | -4.21 | -1.07 | -1.09 | -5.43 | -0.59 | -4.11 | -2.64 | -0.60 | 0.43 | -0.55 | -1.51 | -7.17 | -8.22 | ||||||||||||
| Market Capitalization | 3,660.70M | 2,127.94M | 1,307.92M | 1,638.44M | 1,555.54M | 908.52M | 719.96M | 830.65M | 533.12M | 541.34M | 761.92M | 487.09M | 586.60M | 452.01M | 319.15M | 248.75M | 276.72M | 314.30M | 597.35M | 718.32M | ||||||||||||
| Price to FCFP/FCF | -70.09 | -46.09 | -18.33 | -38.38 | -32.49 | -14.24 | -10.64 | -13.37 | -9.60 | -10.05 | -13.99 | -7.74 | -13.76 | -12.55 | -6.08 | -6.07 | -9.42 | -11.35 | -45.74 | -22.44 | ||||||||||||
| EV to FCF | -60.84 | -36.18 | -12.04 | -26.89 | -20.96 | -6.13 | -3.68 | -5.45 | -1.22 | -1.72 | -6.92 | -0.67 | -6.92 | -4.43 | -0.74 | 0.59 | -0.84 | -2.31 | -25.31 | -12.05 | ||||||||||||
| EV to CFO | -65.00 | -36.77 | -12.59 | -26.99 | -21.05 | -6.30 | -3.73 | -5.48 | -1.22 | -1.73 | -6.75 | -0.67 | -6.69 | -4.35 | -0.74 | 0.62 | -0.83 | -2.32 | -25.59 | -12.06 | ||||||||||||
| Return Ratios | ||||||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -158,510.20% | 2.26% | -205,164.10% | -119,712.50% | -305,596.30% | -370,750.00% | -330,306.67% | -366,090.91% | -286,345.45% | -405,280.95% | -315,927.27% | -444,676.92% | -692,600.00% | -1,241,813.64% | -1,011.21% | |||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -23.94% | -17.72% | -23.22% | -25.21% | -27.07% | -41.72% | -48.81% | -50.71% | -48.04% | -51.13% | -51.08% | -49.89% | -50.87% | -51.22% | -53.96% | -55.57% | -53.71% | -52.95% | -50.37% | -40.86% | ||||||||||||
| Return on Assets [ROA]ROA | -22.78% | -17.08% | -22.50% | -24.16% | -25.61% | -38.61% | -44.72% | -46.20% | -44.02% | -45.63% | -44.51% | -42.69% | -43.95% | -44.51% | -47.12% | -47.71% | -46.04% | -44.67% | -42.89% | -35.05% |